Skip to main content

Value Stock - Dividend - Research Selection

ISIN: , WKN:

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS

2022-11-17
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells (hPSCs) that maximizes the viability of the cells using the Namocell Single Cell

BIO-TECHNE ANNOUNCES OPENING OF NEW IMMUNOASSAY MANUFACTURING FACILITY

2022-11-15
Bio-Techne Corporation (NASDAQ: TECH) today announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility. The expansion more than doubles the operational footprint at Bio-Techne's Wallingford, Connecticut site and provides a five-fold increase in Ella™ immunoassay cartridge production capacity. Ella is an automated multiplexing immunoassay system, that enables rapid and hands-free precision biomarker detection.

Bio-Techne opens new immunoassay manufacturing facility

2022-11-15
Bio-Techne announced the ... TECH

Top 5 3rd Quarter Trades of Au - GuruFocus.com

2022-11-11
GuruFocus Article or News written by insider and the topic is about:

Bio-Techne: Recent Weakness, Charts Suggest It's Now A Buy (Technical Analysis)

2022-11-11
Bio-Techne stock has endured a beating on the chart in FY22. Click here to find out why I rate TECH a speculative buy.

BIO-TECHNE TO PRESENT AT THE STEPHENS ANNUAL INVESTMENT CONFERENCE

2022-11-10
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

Ron Baron Comments on Bio-Tech - GuruFocus.com

2022-11-10
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Guru stock highlight

Ron Baron's Baron Growth Fund - GuruFocus.com

2022-11-10
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Discussion of markets and holdings

BIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE

2022-11-08
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022, at 2:25 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.

BIO-TECHNE TO PRESENT AT THE CREDIT SUISSE 31ST ANNUAL HEALTHCARE CONFERENCE

2022-11-03
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.